Actively Recruiting
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Led by Peng Zhang · Updated on 2025-01-06
60
Participants Needed
1
Research Sites
216 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study targeted patients with resectable stage II-IIIA non-small cell lung cancer with EGFR mutation
CONDITIONS
Official Title
Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- NSCLC patient with EGFR sensitive mutation confirmed by biopsy
- Stage II-IIIA disease as identified by imaging tests
- No systemic metastasis confirmed by multiple scans
- Suitable for radical surgery
- Good lung function to tolerate surgery
- Aged 18 to 75 years
- At least one measurable tumor focus larger than 10 mm by CT
- Normal function of major organs (liver, kidney, blood system)
- ECOG performance status score of 0 or 1
- Female participants of child-bearing potential must have a negative pregnancy test within 7 days before treatment and use reliable contraception during and 30 days after the trial
- Male participants must use condoms during and 30 days after the trial
- Signed informed consent form
You will not qualify if you...
- Prior systemic anti-cancer treatment for NSCLC, including surgery, radiotherapy, chemotherapy, targeted therapy, or experimental therapies
- Unstable systemic diseases such as active infection, uncontrolled hypertension, recent angina, congestive heart failure (NYHA Grade II or higher), recent cardiac infarction, severe arrhythmia, or liver/kidney/metabolic diseases requiring treatment
- HIV positive
- History or current interstitial lung disease
- Major systemic surgery or severe trauma within 3 months before the trial
- Allergy to befotertinib or its components
- Allergy to bevacizumab or its components
- Allergy to platinum-based chemotherapy or its components
- Pregnancy or lactation
- Any condition deemed unsuitable for enrollment by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
Research Team
P
Peng Zhang
CONTACT
Y
Yue Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here